Assessing the U.S. Medical Innovation System
Upload/update your conference materials
-
Kushal T. Kadakia, Sanket S. Dhruva, Joseph S. Ross, Vinay K. Rathi
Clinical and Regulatory Tradeoffs for Innovation: Lessons from the FDA’s Breakthrough Devices Program -
Jennifer L. Kao, Charu N. Gupta
Beyond the Label: Regulatory Arbitrage in Pharmaceutical Market Entry -
S. Sean Tu
Serial Patent Litigation: An Emerging Strategy to Delay Entry of Generic Competition -
Chenxi Xu, Giuseppe Lopomo, David B. Ridley, Peng Sun
Conditional and Lenient Drug Approvals -
Amitabh Chandra, Connie Xu
Scientists and Institutions in Life-Science Discovery -
Hueysin Naci, Jinru Wei, Astrid Van Wilder, James Lomas, Daniel A. Ollendorf, Irene Papanicolas
Quantifying the net health effects of new drugs adopted by Medicare, 2015-2024 -
Boshen Jiao, Ian S. Haworth, Darius N. Lakdawalla
Do We Pay for Innovation? The Rising Returns to Pharmacological Novelty in the U.S. Pharmaceutical Market -
Pierre Azoulay, Wesley H. Greenblatt
Does Peer Review Penalize Scientific Risk Taking? Evidence from NIH Grant Renewals -
Eric Budish, Maya M. Durvasula, Benjamin N. Roin, Heidi L. Williams
Missing Markets for Innovation: Evidence from New Uses for Existing Drugs -
Antonio J. Trujillo, Yongzheng Liang, Manuel Hermosilla, Jeromie Ballreich
Tax Windfall or White Elephant? The Intensive-Margin Innovation Response of U.S. Pharmaceutical Firms to the 2017 Corporate Tax Reform -
Max Mayca, Gerald R. Marschke
Booms, Busts, and the PhD Pipeline: The Career Impacts of Biomedical Science Funding Volatility -
Drishti Baid
Does Brand-to-Brand Competition Reduce Prices of Prescription Drugs?
Send questions to the NBER Conference Department (confer@nber.org).